LobbyingChildren's Hospital Boston lobbying by quarter
Children's Hospital Boston's latest lobbying report covers Q2 2026, at $180K. The four quarters Q4 2025–Q3 2026 total $400K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medical/Disease Research/Clinical Labs.
Children's Hospital Boston
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $400K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $70K | 1 |
| Q1 2023 | $120K | 1 |
| Q2 2023 | $100K | 1 |
| Q3 2023 | $70K | 1 |
| Q4 2023 | $80K | 1 |
| Q1 2024 | $180K | 1 |
| Q2 2024 | $110K | 1 |
| Q3 2024 | $80K | 1 |
| Q4 2024 | $90K | 1 |
| Q1 2025 | $130K | 1 |
| Q2 2025 | $110K | 1 |
| Q3 2025 | $130K | 1 |
| Q4 2025 | $80K | 1 |
| Q1 2026 | $140K | 1 |
| Q2 2026 | $180K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$540.8K · 15 reports
- Medical research and clinical labs$540.8K · 15 reports
- Medicare and Medicaid$540.8K · 15 reports
- Budget and appropriations$47.5K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Centers For Medicare and Medicaid Services (CMS)15 reports
- Health & Human Services, Dept of (HHS)15 reports
- Health Resources & Services Administration (HRSA)15 reports
- HOUSE OF REPRESENTATIVES15 reports
- Natl Institutes of Health (NIH)15 reports
- SENATE15 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseChildren's Hospital Boston | $1.7M | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/22for Q2 | In-house | $180K |
| 04/30for Q1 | In-house | $140K |
| 01/21for Q4 2025 | In-house | $80K |
| 25/10/22for Q3 2025 | In-house | $130K |
| 25/07/22for Q2 2025 | In-house | $110K |
| 25/05/06for Q1 2025 | In-house | $130K |
| 25/02/03for Q4 2024 | In-house | $90K |
| 24/11/01for Q3 2024 | In-house | $80K |
| 24/07/22for Q2 2024 | In-house | $110K |
| 24/04/30for Q1 2024 | In-house | $180K |
| 24/01/24for Q4 2023 | In-house | $80K |
| 23/10/30for Q3 2023 | In-house | $70K |
| 23/08/21for Q2 2023 | In-house | $100K |
| 23/07/24for Q2 2023 | In-house | $100K |
| 23/04/25for Q1 2023 | In-house | $120K |
| 23/01/20for Q4 2022 | In-house | $70K |